Pfizer adds warning to Celebrex arthritis drug

Download PDF Copy

Aug 3 2005

Pharmaceutical giant Pfizer has adapted the label of its Celebrex arthritis drug and added a prominent warning of possible cardiovascular risks, such as increased risk of heart attacks.

This is in line with new warnings concerning other arthritis and pain drugs.

Pfizer say the package insert label of the drug, one of the company's biggest products, recommends that it be prescribed "at the lowest effective dose for the shortest duration".

There has apparently been a sharp decline in sales of Celebrex recently due to safety concerns about the drug.

Pfizer also says U.S. regulators have approved the use of the drug for treatment of ankylosing spondylitis, a form of arthritis that affects the spine.

Posted in: Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Interferon pathway genes linked to treatment success in juvenile arthritis

Myopenia identified as key contributor to muscle loss in rheumatoid arthritis

Immune molecule found to play a key role in regulating inflammation in rheumatoid arthritis

Early intensive therapy shows promise in psoriatic arthritis patients with poor prognostic factors

Nanoparticles could slow rheumatoid arthritis progression and reduce flare severity

HIV treatment linked to risk of early knee osteoarthritis

Single-cell transcriptomes of immune cells offer insight into juvenile idiopathic arthritis

Smart material delivers drugs in response to arthritis flare-ups

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.